Subscribe

Rheumatology Practice Management December 2017 Vol 5 No 6

In the phase 3 TARGET study, sarilumab (150 or 200 mg) plus conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) improved RA signs and symptoms and physical function compared with placebo in adults with active, moderate-to-severe RA who were intolerant of, or showed inadequate response to, tumor necrosis factor (TNF) inhibitors.

The current study reported on updated integrated safety data from 8 randomized trials that further described the safety profile for up to 5.5 years of baricitinib in adult patients with moderately to severely active RA.

This is an analysis of the double-blind, placebo-controlled period 1 of the randomized phase 3 study that evaluated upadacitinib in patients with inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs).

Sarilumab, a human monoclonal antibody against interleukin-6 receptors, is currently approved for patients with moderate-to-severe rheumatoid arthritis (RA), based on efficacy and safety data from several clinical trials.

This post hoc analysis examined efficacy and safety outcomes from patients who completed the ASCERTAIN trial and switched to subcutaneous sarilumab 200 mg q2w.

The phase 3 SIRROUND-D trial demonstrated that sirukumab, a human monoclonal antibody that selectively binds to the interleukin-6 cytokine with high affinity, resulted in significant reduction in rheumatoid arthritis (RA) signs and symptoms, and inhibited radiographic progression at week 52 compared with placebo in patients with active RA despite disease-modifying antirheumatic drug (DMARD) treatment.

The efficacy and safety of sarilu­mab, a human monoclonal antibody blocking the interleukin-6 receptor alpha, were evaluated for treatment of rheumatoid arthritis (RA) in 3 clinical trials, including the MOBILITY trial.

An analysis compared patient-reported outcomes (PROs) from the ORAL Strategy trial, a phase 3b/4, triple-dummy, controlled trial that randomized patients with RA 1:1:1 to receive tofacitinib monotherapy 5 mg twice daily, tofacitinib 5 mg twice daily plus methotrexate (MTX), or subcutaneous ada­limumab (40 mg every other week) plus MTX, with MTX dosed at 15 mg to 25 mg per week.

Using the Corrona Rheumatoid Arthritis (RA) registry, the current study sought to assess in routine clinical practice the effectiveness of tocilizumab monotherapy versus TNFi plus varying doses of MTX in patients with RA and prior exposure to TNFi.

This retrospective analysis of the Optum One electronic health record (EHR) databases from various Integrated Delivery Networks (IDNs) and large group practices across the United States was conducted to examine the EHR reporting rates of several clinical measures among patients with rheumatoid arthritis (RA) who received a biologic or a targeted synthetic disease-modifying antirheumatic drug (tsDMARD).

Page 2 of 3
Results 11 - 20 of 27
  • American Health and Drug Benefits
  • Lynx CME
  • Value Based Care in Rheumatology
  • Oncology Practice Management
  • Urology Practice Management

Search